Frazier Healthcare Partners overview
Stories about Frazier Healthcare Partners
Frazier Healthcare Partners closes latest fund at $780m
The Seattle-based firm closes its second exclusive growth buyout vehicle at hard cap.
Frazier Healthcare closes Fund VIII on $525m
Fund VIII is the firm's first dedicated growth buyout firm to focus exclusively on healthcare companies in the lower mid-market.
Frazier Healthcare Partners contact information
Offices
Two Union Square, 601 Union Street, Suite 3200, Seattle, 98101, United StatesContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Ms. Carol Eckert | Job titleSenior Vice President, Investor Relations | LocationSeattle, United States | Email  ----------- |
| Mr. Steve Bailey | Job titleChief Financial Officer, Chief Compliance Officer and Partner | LocationSeattle, United States | Email ---------- |
| Mr. Andy Caine | Job titleChief Operating Officer and Partner | LocationSeattle, United States | Email ------- |
| Mr. Gordon Empey | Job titleChief Operating Officer, General Counsel and Partner, Frazier Life Sciences | LocationSeattle, United States | Email -------- |
Frazier Healthcare Partners funds managed
Funds in market: 3
| Fund | Fund size | Open date | Strategy |
|---|---|---|---|
Fund size -------- | Open dateMar 2026 | Strategy -------- | |
Fund size --------- | Open dateDec 2025 | Strategy ----------- | |
Fund size ----------- | Open dateSep 2024 | Strategy ------- | |
Closed funds: 16
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size --------- | Close dateJul 2025 | Strategy ----------- | |
Fund size ------- | Close dateNov 2024 | Strategy ------- | |
Fund size --------- | Close dateNov 2024 | Strategy --------- | |
Stories that mention Frazier Healthcare Partners
Side Letter: Distribution disruption
In today's edition, AI disruption adds fresh pressure to deliver speedy exits; PE reporting inefficiencies are creating friction in the wealth community;Private funds could see important legislative change come December.
Petershill delisting underscores concerns over public-private knowledge gap
Industry participants say GP stakes may not be well understood by the market and analysts.
CHART: The biggest dedicated life sciences capital raisers
Dedicated life sciences firms with strong AUM growth have been prime targets for larger GPs recently – here's a list of firms ranked by capital raised.
PEI Awards 2018: Global winners
Energy, healthcare, technology, consumer, long-term, frontier markets and impact investment firms of the year.
Mid-teens net IRR the ‘new normal’
High prices and lower debt multiples will take their toll on returns, according to research from alternatives manager Partners Group.